显微镜辅助分期肝切除术的关联肝分区和门静脉结扎的小鼠模型
January 19th, 2024
1.5K views
将肝分区和门静脉结扎术关联用于分期肝切除术 （ALPPS） 已被证明可在第一阶段手术后数周后导致显着的肝脏再生。已经开发了经过 ALPPS 的动物模型，以探索潜在的肝脏再生能力并取得良好的临床结果。
ALPPS 可迅速促进肝脏再生。然而，相当小的动物模型和节奏视觉的机制仍然不足。该模型允许研究参与严重肝损伤肝脏再生的分子和细胞途径，与 ARVPS 和 PMX 小鼠模型的 A 一起，商业研究表明，PMX 3 和第二轮的平衡在比较中调节触觉在体质下被杀死，强加手术肝脏再生。
单细胞测序。单细胞攻击测序。与单细胞一样，CRISPR 为在正常肝脏和列表肝脏中发现以前未知的细胞类型和亚型铺平了道路。
ARBs 技术用于无法通过手术切除的肝肿瘤患者。手术后剩余肝脏的再生能力对患者的生存至关重要。然而，AFVBS 后的潜在机制仍然未知。
基于以往关于大鼠和小鼠 AFVBS GECo 模型的报道，我们构建了小鼠 GECo 方案，它与临床操作和天然肢体一致。
概述
联合肝脏分割与门静脉结扎分期肝切除术（ALPPS）促进手术后显著的肝脏再生。本研究利用动物模型探讨肝脏再生的机制，重点关注分子途径。
关键研究组成部分
科学领域
- 肝脏再生
- 手术技术
- 动物模型
背景
- ALPPS增强了严重损伤后的肝脏再生。
- 啮齿动物模型用于研究再生机制。
- 了解细胞途径对改善临床结果至关重要。
- 最近的研究突出了Gata3和Ramp2在肝细胞中的作用。
研究目的
- 调查ALPPS术后肝脏再生机制。
- 探索再生所涉及的分子和细胞途径。
- 利用先进技术识别肝脏中的新细胞类型。
使用的方法
- ALPPS手术技术
- PMX小鼠模型
- 单细胞测序
- 单细胞CRISPR技术
主要结果
- ALPPS显著促进肝脏再生。
- Gata3和Ramp2的平衡对肝细胞功能至关重要。
- 在肝组织中识别了新的细胞类型和亚型。
- 对细胞途径的洞察可以增强手术结果。
结论
- ALPPS对于不可切除肝脏肿瘤的患者是有效的。
- 了解再生机制可以带来更好的治疗方法。
- 未来的研究应该关注被确定的途径以便于临床应用。
常见问题
什么是ALPPS？
ALPPS代表联合肝脏分割与门静脉结扎分期肝切除术，是一种增强肝脏再生的手术技术。
ALPPS如何促进肝脏再生？
ALPPS通过诱导一系列生物反应促进手术后肝脏的生长。
本研究使用了哪些动物模型？
使用啮齿动物模型，特别是PMX小鼠模型，来研究肝脏再生机制。
关于Gata3和Ramp2的主要发现是什么？
肝细胞中Gata3和Ramp2的平衡对调节手术后肝脏再生至关重要。
采用了哪些技术来研究肝脏再生？
技术包括单细胞测序和单细胞CRISPR，用于探索细胞途径并识别新的细胞类型。
这项研究的意义是什么？
这项研究为肝脏再生机制提供了见解，可以改善肝脏肿瘤患者的手术结果。
Executive Industry Relevance
Robust preclinical models of ALPPS enable mechanistic de-risking of liver regeneration pathways, addressing a critical bottleneck in hepatic surgery R&D. By replicating staged hepatectomy and portal vein ligation in mice, this approach supports predictive confidence in target validation for hepatic regenerative therapies. The model's capacity to interrogate molecular drivers of regeneration informs risk-adjusted portfolio decisions in early discovery and translational research.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of regenerative pathways and molecular targets in a controlled in vivo context.
- Supports functional validation of candidate genes such as Gata3 and Ramp2 in hepatocyte-driven regeneration.
- Facilitates mechanistic de-risking by linking pathway modulation to regenerative outcomes.
- Provides a platform for hypothesis-driven exploration of hepatic repair mechanisms.
Screening & Assay Development
- Establishes a reproducible animal model for quantitative assessment of liver regeneration.
- Supports standardization of injury and regeneration endpoints for downstream screening workflows.
- Enables collection of quantitative outputs such as cellular proliferation and inflammatory marker levels.
- Prepares validated biological systems for compound or genetic perturbation studies.
Translational & Preclinical Research
- Aligns preclinical findings with disease-relevant mechanisms of hepatic regeneration.
- Enables continuity from discovery-stage target validation to preclinical efficacy studies.
- Supports identification of translational biomarkers linked to regenerative capacity.
- Informs risk-adjusted advancement of regenerative medicine candidates.
Pipeline & Workflow Integration
This mouse ALPPS model bridges early discovery and preclinical validation, enabling mechanistic studies and quantitative readouts that inform lead identification and translational research.
- Discovery Biology: Supports hypothesis testing of regenerative pathways and target gene function in vivo.
- Screening: Provides standardized, reproducible endpoints for evaluating regenerative interventions.
- Analytics: Delivers quantitative measurements of proliferation and inflammatory markers for comparative analysis.
- Translational Research: Connects mechanistic insights to preclinical models relevant for hepatic disease and regeneration.
- Enterprise Reuse: Offers a reusable platform for iterative target validation and mechanistic studies across programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in regenerative target validation and pathway prioritization.
- Operational Value: Enhances reproducibility and standardization of in vivo regenerative studies.
- Strategic Value: Supports informed go/no-go decisions and reduces late-stage biological risk in hepatic portfolios.
- Portfolio Impact: Enables risk-adjusted prioritization of regenerative medicine assets and translational candidates.
Implementation Considerations
- Requires expertise in microsurgical techniques and animal model management.
- Demands access to advanced analytical tools for single-cell sequencing and molecular profiling.
- Necessitates cross-team standardization of surgical and analytical protocols.
- Adaptation may be needed for different genetic backgrounds or disease models.
- Limitations include model-specific regenerative kinetics and potential species differences.
Biopharma FAQs
Why does null hypothesis testing matter for ALPPS target validation?
Null hypothesis testing in the ALPPS mouse model enables rigorous evaluation of whether specific genes or pathways, such as Gata3 or Ramp2, are required for liver regeneration. This approach reduces mechanistic ambiguity and supports confident target validation decisions in hepatic R&D portfolios.
How does independent variable isolation fit the ALPPS discovery pipeline?
Isolating variables like portal vein ligation or gene perturbation in the ALPPS model allows teams to attribute regenerative outcomes to specific interventions. This clarity is essential for mechanistic de-risking and for prioritizing targets in early-stage discovery workflows.
What do quantitative dependent variable measurements enable in ALPPS studies?
Quantitative measurements, such as cellular proliferation rates and interleukin-6 levels, provide objective endpoints for comparing regenerative responses. These outputs support data-driven advancement and cross-study reproducibility in preclinical hepatic research.
Why are replication requirements critical for ALPPS cross-functional collaboration?
Replication of ALPPS procedures and outcomes ensures that findings are robust and transferable across teams, facilitating standardized data generation and collaborative decision-making in multi-site R&D environments.
What statistical analysis capabilities are required before ALPPS model implementation?
Robust statistical analysis is needed to interpret regenerative endpoints, compare intervention groups, and validate reproducibility. This ensures that observed effects in the ALPPS model are significant and actionable for downstream translational research.
